Press Releases

SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the diseases of ageing, today announces that it has been awarded a £571,350 grant from Innovate UK, the UK’s innovation agency, towards the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Built on 15 years of pioneering research, SENISCA’s proprietary technology is harnessing RNA biology to rejuvenate age

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule. The article, entitled “mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity,” includes preclinical

Strateos, a leading provider of lab automation software and remote access laboratories for life science research, today announced a strategic shift aimed at meeting the growing demand from its life sciences customers seeking to establish on-site implementations of fully automated cloud labs that can be accessed from anywhere in the world. In line with this shift, Strateos is reorganizing and expanding its business to focus on design-and-deployment engagements. “As a pioneer in

PCI Pharma Services  a leading global contract development and manufacturing organization , today announced that three new state-of-the-art automated sterile fill-finish machines at its San Diego and Melbourne facilities are now fully operational. The innovative machinery from Cytiva can be used to fill various sterile medications into vials and syringes for small-to-mid scale client needs. The equipment, paired with PCI’s end-to-end services, accelerates Speed to Study™, and

IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, and Second Sight Solutions, a health technology company providing pharmaceutical manufacturers the definitive solution to transparency and compliance in the 340B Program, announced plans for a new joint initiative for 340B Drug Pricing Program duplicate discount prevention. The initiative, when implemented, will be capable of integrating 340B claim

Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine.  The data presented showed that in the vaccinated women who have been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels.  The presentation was made by G. Thomas Budd, M.D., of Cleveland Clinic's Taussig Canc

Nektar Therapeutics today announced a strategic reprioritization and cost restructuring plan that includes a new pipeline focus on immunology, as well as several cost reduction initiatives, which the company expects will significantly reduce future operating expenses and extend its cash runway into the middle of 2026. Key elements of the new plan include: Prioritize REZPEG development: Nektar intends to work with Eli Lilly to ensure the continuation of REZPEG devel

Ahead of next week’s CPHI Japan 2023 (19-21), one keynote speaker – Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline – predicts that the continued rise of biopharma innovation in China is the big macro trend in the APAC region that could potentially lead to shifts in outsourcing and manufacturing strategies regionally. “Historically, we have seen a dual strategy of focusing on China and the US for emerging innovators in China. However, a serie

CANbridge Pharmaceuticals, Inc.a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that the American Society for Gene and Cell Therapy (ASGCT) has accepted the following abstract for presentation at the ASCGT Annual Meeting, May 16-20, in Los Angeles, CA. Title: Low-dose intracerebroventricular delivery of a second-gen

The Center for iPS Cell Research and Application, Kyoto University and Astellas Pharma Inc.  entered into the second phase of a joint research agreement to further promote the utilization of differentiated cells and tissues derived from human induced pluripotent stem cells1 and to create innovative medical solutions. During the first phase (July 2017 to March 2023), the two parties conducted comprehensive joint research on drug discovery applications of iPS cells. In the second